{"nctId":"NCT00448591","briefTitle":"A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.","startDateStruct":{"date":"2006-09"},"conditions":["Breast Cancer"],"count":2296,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: Taxane-based chemotherapy"]}],"interventions":[{"name":"bevacizumab [Avastin]","otherNames":[]},{"name":"Taxane-based chemotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients, \\>=18 years of age;\n* HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;\n* candidates for chemotherapy.\n\nExclusion Criteria:\n\n* previous chemotherapy for metastatic or locally recurrent breast cancer;\n* concomitant hormonal therapy for metastatic or locally recurrent disease;\n* concomitant Herceptin therapy for treatment of metastatic or locally recurrent HER-2 positive disease;\n* previous radiotherapy for treatment of metastatic disease;\n* evidence of CNS metastases.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Percentage of Participants With Disease Progression","description":"Disease progression was assessed by the investigator per standard clinical practice using Response Evaluation Criteria In Solid Tumors (RECIST) criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP)","description":"TTP was defined as the time period from the start of first-line therapy to investigator-assessed disease progression. Tumor assessments were performed according to standard clinical practice using NCI criteria. Participants who had not progressed at the time of analysis (including those who died before progressive disease \\[PD\\]) or who were lost to follow-up were censored at the last bevacizumab administration date. Time to disease progression was determined by Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Recorded Death","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall Survival was defined as the time from start of first-line therapy to death due to any cause. Participants for whom no death was captured in the clinical database were censored at the last date they were known to be alive. Median time to overall survival was calculated by Kaplan Meier estimates.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Best Overall Response to Treatment","description":"Best overall response is defined as the best response shown throughout the study. Tumor assessment was performed by the investigator using standard clinical practice.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs)","description":"Adverse events (including laboratory abnormalities) were assessed by the investigator according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) grading systems.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":672,"n":2264},"commonTop":["Fatigue","Alopecia","Epistaxis","Hypertension","Nausea"]}}}